97275 ⎘
Immunoglobulins specific features characterized by immunoglobulin fragments; Constant or Fc region; Isotype CH1 domain
Multivalent Antibody Complexes Targeting IGF-1R Show Potent Toxicity Against Solid Tumors
#602Anti-human vista antibodies and use thereof
#603BISPECIFIC ANTIBODY MOLECULE
#604Neuropilin-1 specific binding peptide, fusion protein fused with same, and use thereof
#605Lysine conjugated immunoglobulins
#606Modified-IgG antibodies that bind transforming growth factor-β1 with high affinity, avidity and specificity
#607Multispecific antigen binding fragments and multispecific antibodies derived therefrom comprising mutant CH1 and CL-kappa domains
#608COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS
#609Anti-wall teichoic antibodies and conjugates
#610IgG bispecific antibodies and processes for preparation
#611Methods of immune therapy with anti-CD154 antibodies having Fc modifications
#612Hyperglycosylated binding polypeptides
#613Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseases
#614MULTISPECIFIC ANTIBODIES
#615Asymmetric multispecific antibodies
#616Fusion protein comprising three binding domains to 5T4 and CD3
#617ANTI-GLYCOPROTEIN IIb/IIIa ANTIBODIES
#618Isolated nucleic acid encoding an anti-IGF-1R antibody
#619Dual Variable Domain Immunoglobulin and Uses Thereof
#620Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunit
#621Bispecific antibodies against CD3ϵ and BCMA
#622Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
#623Anti-human vista antibodies and use thereof
#624Anti-human vista antibodies and use thereof
#625Anti-human vista antibodies and use thereof
#626Bispecific HER2 antibodies
#627Methods of modifying antibodies for purification of bispecific antibodies
#628Site-specific antibody-drug conjugation through glycoengineering
#629MULTIVALENT ANTIGEN-BINDING PROTEINS
#630Antibodies against CD73
#631Antibodies to CD40 with enhanced agonist activity
#632BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR
#633Bispecific antibodies and methods of use in ophthalmology
#634BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
#635Anti-CD40 antibodies
#636Genetic engineering of non-human animals for the production of chimeric antibodies
#637CONSTANT REGION ANTIBODY FUSION PROTEINS AND COMPOSITIONS THEREOF
#638Anti-cancer antibodies with reduced complement fixation
#639Multispecific antigen binding proteins
#640Modified antigen binding polypeptide constructs and uses thereof
#641Anti-CD3 antibodies and methods of use
#642Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
#643Genetic engineering of non-human animals for the production of chimeric antibodies
#644Genetic engineering of non-human animals for the production of chimeric antibodies
#645Genetic engineering of non-human animals for the production of chimeric antibodies
#646Genetic engineering of non-human animals for the production of chimeric antibodies
#647Bispecific T cell activating antigen binding molecules
#648Genetic engineering of non-human animals for the production of chimeric antibodies
#649Genetic engineering of non-human animals for the production of chimeric antibodies
#650Cysteine engineered antibodies for site-specific conjugation
#651Genetic engineering of non-human animals for the production of chimeric antibodies
#652Bi-and monospecific, asymmetric antibodies and methods of generating the same
#653ANTIBODIES WITH MODIFIED ISOELECTRIC POINTS
#654Antibodies for epidermal growth factor receptor 3 (HER3)
#655Antibody variants composition
#656IMMUNOGLOBULIN VARIANTS AND USES THEREOF
#657Modified antibodies containing modified IGG2 domains which elicit agonist or antagonistic properties and use thereof
#658Antigen binding formats for use in therapeutic treatments or diagnostic assays
#659Antigen binding proteins to oncostatin M (OSM)
#660TETRAVALENT MULTISPECIFIC ANTIBODIES
#661Fab FRAGMENT SPECIFICALLY BINDING TO EGFR
#662HUMANIZED ANTIBODIES
#663MULTISPECIFIC ANTIBODIES
#664Heavy chain only antibodies to ANG-2
#665BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#666BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#667Pyrrolobenzodiazepine antibody drug conjugates and methods of use
#668Dock-and-Lock (DNL) Complexes for Therapeutic and Diagnostic Use
#669Heterodimeric antibodies to CD3 X CD123
#670Heterodimeric antibodies to CD3 X CD20
#671Humanized anti-CXCR5 antibodies, derivatives thereof and their uses
#672Heavy chain only antibodies to PDGF
#673Bispecific HER2 antibodies and methods of use
#674ECZEMA TREATMENT
#675MULTISPECIFIC ANTIBODY ANALOGS COMPRISING A COMMON LIGHT CHAIN, AND METHODS OF THEIR PREPARATION AND USE
#676Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof
#677Multispecific NK engager proteins
#678Dock-and-Lock (DNL) Vaccines for Cancer Therapy
#679Heterodimeric antibodies that bind CD3 and tumor antigens
#680OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
#681Optimized Fc variants and methods for their generation
#682Stable protein solution formulation containing high concentration of an anti-VEGF antibody
#683NOVEL METHODS FOR THE STABILISATION OF IMMUNOGLOBULIN CONSTANT DOMAINS
#684Multivalent antibodies
#685Class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type I receptor (IGF-1R)
#686Recombinant polypeptide production methods
#687Multispecific domain exchanged common variable light chain antibodies
#688Optimized Fc variants and methods for their generation
#689Dual specificity antibody fusions
#690DNA antibody constructs and method of using same
#691Fabs-in-tandem immunoglobulin and uses thereof
#692Fabs-in-tandem immunoglobulin and uses thereof
#693Anti-claudin antibodies and methods of use
#694Human IgG1 derived antibody with pro-apoptotic activity
#695Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity
#696Combination Therapy With Anti-CD74 and Anti-CD20 Antibodies Provides Enhanced Toxicity to B-Cell Diseases
#697Heterodimeric antibodies that bind CD3 and tumor antigens
#698Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
#699NON-HUMAN MAMMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES
#700Non-human mammals for the production of chimeric antibodies
#701NON-HUMAN MAMMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES
#702Non-human mammals for the production of chimeric antibodies
#703Non-human mammals for the production of chimeric antibodies
#704Non-human mammals for the production of chimeric antibodies
#705Non-human mammals for the production of chimeric antibodies
#706Heterodimeric antibodies that bind CD3 and CD38
#707Tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules
#708Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
#709Stable and soluble antibodies inhibiting TNFα
#710HETERODIMERIC ANTIBODIES INCLUDING BINDING TO CD8
#711ANTIBODIES WITH ULTRALONG COMPLEMENTARITY DETERMINING REGIONS
#712Antibody constant region variant
#713Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunits
#714Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor
#715Antibodies against CD73
#716Construction and application of bispecific antibody HER2xCD3
#717Glycoengineered antibody drug conjugates
#718Methods for treating neovascular age-related macular degeneration
#719Recombinant antibody composition
#720ANTIBODIES DIRECTED AGAINST AMYLOID-BETA PEPTIDE AND METHODS USING SAME
#721Production of antibody formats and immunological applications of said formats
#722Bispecific T cell activating antigen binding molecules
#723Anti-wall teichoic antibodies and conjugates
#724Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
#725Monospecific polypeptide reagents
#726Methods for producing fabs and bi-specific antibodies
#727Antibody and antibody fragment introduced new modification sites
#728CHARGE-ENGINEERED ANTIBODIES OR COMPOSITIONS OF PENETRATION-ENHANCED TARGETING PROTEINS AND METHODS OF USE
#729Antibody fragments, compositions and uses thereof
#730TETRAVALENT BISPECIFIC ANTIBODIES
#731Dual PDGF/VEGF antagonists
#732Multispecific constructs
#733Anti-wall teichoic antibodies and conjugates
#734Modified Antigen Binding Molecules With Altered Cell Signaling Activity
#735ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TRACT
#736Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
#737Antibody constant region variant
#738Methods and antibody compositions for tumor treatment
#739Protective anti-ETEC antibody
#740PURIFICATION OF HETERO-DIMERIC IMMUNOGLOBULINS
#741MUTIVALENT ANTIGEN-BINDING PROTEINS
#742IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
#743Anti-CD3 antibodies and methods of use
#744Serpin fusion polypeptides and methods of use thereof
#745WAP domain fusion polypeptides and methods of use thereof
#746Bispecific antibody molecule
#747Variant immunoglobulins with improved manufacturability
#748Readily isolated bispecific binding molecules with native format having mutated constant regions
#749Hyperglycosylated binding polypeptides
#750Anti-cancer antibodies with reduced complement fixation
#751Antigen binding proteins to Oncostatin M (OSM)
#752Anti-c-met-antibody formulations
#753Humanized antibodies
#754Methods for identification of sites for IgG conjugation
#755ANTI-TNF/IL-17 DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF
#756Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
#757Sequence symmetric modified IGG4 bispecific antibodies
#758Sequence asymmetric modified IgG4 bispecific antibodies
#759Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
#760Anti-wall teichoic antibodies and conjugates
#761Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
#762Assembly of bispecific antibodies
#763Anti-IL-6 receptor antibodies and methods of use
#764Site-specific antibody-drug conjugation through glycoengineering
#765Hybrid constant regions
#766Antibodies with modified isoelectric points
#767Multispecific antigens binding fragments and multispecific antibodies derived therefrom comprising mutant CH1 and CL-κ domains
#768Anti-FcRH5 antibodies and immunoconjugates and methods of use
#769Antigen binding formats for use in therapeutic treatments or diagnostic assays
#770Antigen-binding protein directed against epitope in the CH1 domain of human IgG antibodies
#771Serpin fusion polypeptides and methods of purification thereof
#772Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
#773Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
#774Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
#775Antigen binding proteins to oncostatin M (OSM)
#776Protein complexes for antigen binding and methods of use
#777Antibody constant region variants with reduced Fcgammar binding
#778Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
#779MULTIVALENT ANTIBODIES
#780ECZEMA TREATMENT
#781WAP domain fusion polypeptides and methods of use thereof
#782Serpin fusion polypeptides and methods of use thereof
#783ANTI-C-MET ANTIBODY FORMULATIONS
#784Dual Variable Domain Immunoglobulin and Uses Thereof
#785Methods of treating mucositis using anti-TNF antibodies
#786Anti-CD40 antibodies
#787Multivalent Antibodies
#788Monospecific polypeptide reagents
#789Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
#790Optimized Fc variants and methods for their generation
#791Anti-IL-6 receptor antibodies and methods of use
#792Methods for identification of sites for IgG conjugation
#793Variant immunoglobulins with improved manufacturability
#794Antibodies for epidermal growth factor receptor 3 (HER3)
#795Antibody Constant Region Variant
#796Antibody constant region variant
#797Stable and soluble antibodies inhibiting TNFα
#798Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
#799Antibodies with modified isoelectric points
#800Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
#801Antibody variants composition
#802Antibody and antibody fragment introduced new modification sites
#803Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
#804SYNTHETIC IMMUNOGLOBULIN DOMAINS WITH BINDING PROPERTIES ENGINEERED IN REGIONS OF THE MOLECULE DIFFERENT FROM THE COMPLEMENTARITY DETERMINING REGIONS
#805Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells
#806Bispecific, bivalent anti-VEGF/anti-ANG-2 antibodies
#807Non-human mammals for the production of chimeric antibodies
#808Dock-and-lock (DNL) vaccines for cancer therapy
#809Humanized antibodies
#810Antibodies directed against amyloid-beta peptide and methods using same
#811Cysteine Engineered Antibodies For Site-Specific Conjugation
#812Humanized anti-CXCR5 antibodies, derivatives thereof and their use
#813Recombinant antibody composition
#814Methods of using anti-TNF antibodies for treating radiation damage to the digestive tract
#815Anti-FcRH5 antibodies and immunoconjugates and methods of use
#816Dual specificity antibody fusions
#817MULTISPECIFIC EPITOPE BINDING PROTEINS AND USES THEREOF
#818Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
#819Ligand
#820Dock-and-lock (DNL) vaccines for cancer therapy
#821Dual variable domain immunoglobulin and uses thereof
#822SYNTHETIC IMMUNOGLOBULIN DOMAINS WITH BINDING PROPERTIES ENGINEERED IN REGIONS OF THE MOLECULE DIFFERENT FROM THE COMPLEMENTARITY DETERMINING REGIONS
#823Methods of modifying antibodies for purification of bispecific antibodies
#824Stable and soluble antibodies inhibiting TNFα
#825Production of antibody formats and immunological applications of said formats
#826Bivalent, bispecific antibodies
#827BINDING MOLECULES
#828MULTISPECIFIC EPITOPE BINDING PROTEINS AND USES THEREOF
#829Immunoglobulin variants and uses thereof
#830Anti-cancer antibodies with reduced complement fixation
#831Optimized Fc variants and methods for their generation
#832Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
#833Optimized Fc variants and methods for their generation
#834Optimized Fc variants and methods for their generation
#835Binding constructs and methods for use thereof
#836Recombinant antibody composition
#837Modified antigen binding molecules with altered cell signaling activity
#838Dual variable domain immunoglobulin and uses thereof
#839Antibodies directed against amyloid-beta peptide and nucleic acids encoding same
#840Immunoglobulin variants and uses thereof
#841Immunoglobulin variants and uses thereof
#842Anti-cancer antibodies with reduced complement fixation
#843Vista antigen-binding molecules
#844HER3 antigen-binding molecules